With the rapid advancement of metabolic medicine, New Zealanders now have access to a variety of clinical options for managing weight. While traditional advice often focused solely on lifestyle, modern medicine recognises that biological factors—such as hormones and genetics—play a significant role in how our bodies regulate weight. Understanding how different weight loss treatments function allows patients to make informed decisions alongside their healthcare providers.

GLP-1 Receptor Agonists

The most common class of modern weight loss injections in NZ includes medications like Wegovy (semaglutide) and Saxenda (liraglutide). These work by mimicking a naturally occurring hormone called glucagon-like peptide-1 (GLP-1).

When you eat, your body releases GLP-1 to signal to the brain that you are full. These treatments enhance that signal, significantly reducing appetite and “food noise.” They also slow down gastric emptying, meaning food stays in the stomach longer, extending the feeling of satiety. Wegovy is typically administered once weekly, while Saxenda is a daily injection.

Dual-Agonist Treatments (GIP and GLP-1)

The latest evolution in weight management is represented by Mounjaro (tirzepatide). This treatment is a dual agonist, meaning it mimics two hormones: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide).

By targeting both receptors, Mounjaro not only suppresses appetite but is also thought to improve how the body breaks down sugars and fats. Clinical data often shows that this dual action can lead to a higher percentage of total body weight loss compared to single-hormone treatments, making it a powerful option for those with significant metabolic hurdles.

Oral Weight Management Medications

For those who prefer not to use injections, oral medications remain an option in the New Zealand clinical landscape. These treatments, such as phentermine, work differently by stimulating the central nervous system to suppress appetite.

Unlike the hormone-mimicking injections, these are often intended for shorter-term use (usually up to three months) and focus more on reducing hunger through the “fight or flight” response. They are generally considered less potent for long-term weight loss than GLP-1 or dual-agonist injections but can be effective as part of a supervised, kick-start plan.

Choosing the Right Approach in NZ

The choice between these treatments depends on several factors:

• Efficacy Requirements: How much weight needs to be lost to improve health markers like blood pressure or glucose levels.

• Tolerability: How an individual’s digestive system responds to hormonal changes.

• Cost and Accessibility: In NZ, many of these medications are currently unfunded for weight loss, so private costs vary.

• Lifestyle Compatibility: Whether a daily pill, a daily injection, or a weekly injection fits best into a patient’s routine.

Ultimately, all these medical treatments are designed to be “tools in the shed.” They work most effectively when integrated into a comprehensive health plan that includes nutritional guidance, physical activity, and regular clinical monitoring by a registered professional.